Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity
Authors: Tsagarakis  , Vasiliou  , Kokkoris  , Stavropoulos  , Thalassinos  
Published: March 2003

OBJECTIVE

The desmopressin test has recently been introduced in clinical practice as an adjunctive tool in the differential diagnosis of ACTH–dependent Cushing's syndrome (CS). It has been reported that the majority of patients with pituitary‐dependent CS (Cushing's disease, CD) respond to desmopressin, while no such response is usually observed in other forms of this syndrome. In the present study, the responsiveness of the HPA axis to desmopressin was studied in a group of obese subjects. In addition, the ability of desmopressin administration to differentiate between patients with obesity and the various forms of Cushing's syndrome was investigated.

DESIGN AND SUBJECTS

Cortisol and ACTH responses to the administration of desmopressin (10 μg bolus i.v.) were examined in 20 consecutive patients with obesity (14 women and six men; BMI range: 34.5–66.7 kg/m2). Obese subjects had no clinical stigmata of CS. In all obese patients, either an overnight (dex 1 mg at 2300 h) (n = 8) or a formal low‐dose (dex 0.5 mg 6‐hourly for 2 days) (n = 12) dexamethasone suppression test was performed for the exclusion of Cushing's syndrome. Three of eight subjects showed failure of cortisol suppression (i.e. F > 28 nmol/l) to the overnight dexamethasone suppression test, but they had undetectable cortisol levels (< 28 nmol/l) on further testing with the formal 2‐day test. All but two of the remaining subjects had undetectable cortisol levels (< 28 nmol/l) following the formal 2‐day, low‐dose, dexamethasone suppression test. For comparison, desmopressin responses were also tested in 33 patients with CS of varied aetiologies (25 patients with pituitary‐dependent CS, three patients with occult ectopic ACTH secretion and five patients with primary adrenal CS). A positive response was considered to be an increment greater than 20% and 50% from baseline levels of cortisol and ACTH, respectively.

RESULTS

Mean cortisol (F) and ACTH levels did not differ from the baseline at any time point following desmopressin administration in the obese group (basal F: 417 ± 41, peak F: 389 ± 32 nmol/l, P > 0.05; basal ACTH: 33.5 ± 4.3, peak ACTH: 50.6 ± 16.6 ng/l, P > 0.05), or in patients with occult ectopic or primary adrenal CS. In contrast, in the group of patients with CD, there was a significant rise in the mean ACTH and F levels from baseline (basal F: 725 ± 50, peak F: 1010 ± 64 nmol/l, P < 0.01; basal ACTH: 88.6 ± 11.8, peak ACTH: 351 ± 64 ng/l, P < 0.01). Cortisol responses greater than 20% from baseline were observed in 21/25 (84%) patients with CD, but in only 3/20 (15%) of the obese patients. With regard to ACTH, increments greater than 50% over baseline were observed in 23/25 (92%) of patients with CD, and in only 3/20 (15%) of the obese patients. As previously reported, none of the patients with occult ectopic ACTH secretion or primary adrenal CS had a positive response.

CONCLUSIONS

The prevalence of subjects who met the criteria adopted to define positive cortisol and ACTH responses to the desmopressin test was significantly higher in the group of patients with Cushing's disease than in the group of patients with obesity. It is therefore suggested that this test may be occasionally useful in the differentiation between simple obesity and the pituitary‐dependent form (but not other forms) of Cushing's syndrome.